World's largest hearing-aid maker, also selling cochlear implants (Advanced Bionics) and audiological equipment.
World's largest hearing-aid maker, also selling cochlear implants (Advanced Bionics) and audiological equipment.
Sells hearing aids both to independent audiologists and hearing-care chains and through its own retail clinics (AudioNova), which keeps more of the margin per device; hearing aids, led by the Phonak brand, carry most of the business. Cochlear implants through Advanced Bionics are a smaller business.
In one line: A much larger version of Eargo, the US hearing-aid company.
Moat: narrow (brand, distribution, switching costs). Audiologist relationships, owned retail clinics and R&D scale support share as hearing-loss diagnosis rises.
Headquarters: Stäfa, Switzerland · Founded: 1947 · Employees: 18,447
Size Sonova (SOON.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $19.8B, the 26th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 290.60 on 18 Nov 2026.
Performance Over six months the shares gained 39.9%, against +25.9% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue fell 5.8% over the last twelve months (peer median +7.6%); the operating margin is 22.7% (peer median 17.0%).
Valuation It trades at 25.3× forward earnings against a peer median of 28.0× (8th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 11.0 points above its cost of capital (6.0% WACC).
Next results Next results expected around 18 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 3.62B | CHF 3.61B | CHF 3.61B | CHF 3.63B | CHF 3.74B |
| Revenue growth | — | 0% | 0% | -3% | — |
| Gross profit | CHF 2.72B | CHF 2.60B | CHF 2.63B | CHF 2.56B | CHF 2.59B |
| EBITDA | CHF 1.06B | CHF 968M | CHF 1.03B | CHF 940M | CHF 1.00B |
| Net income | CHF 493M | CHF 431M | CHF 540M | CHF 601M | CHF 648M |
| Free cash flow | CHF 695M | CHF 603M | CHF 688M | CHF 646M | CHF 666M |
| Capital expenditure | CHF 116M | CHF 103M | CHF 132M | CHF 129M | CHF 154M |
| Total debt | n/a | CHF 1.71B | CHF 1.76B | CHF 1.79B | CHF 1.81B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sonova SOON.SW | $19.8B | +40% | -6% | 23% | 25.3× | 6.0% |
| Demant A/S DEMANT.CO | $10.4B | +39% | +10% | 18% | 23.2× | 5.8% |
| GN Store Nord A/S GN.CO | $2.52B | +25% | -35% | 3% | n/a | 20.7% |
| Cochlear COH.AX | $6.72B | +58% | -1% | 13% | 29.1× | 23.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SOON.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.3% | +5.7% | 8th lowest of 21 |
| 6-month return | +39.9% | +25.9% | 5th highest of 21 |
| Distance from 52-week high | -1.6% | -11.1% | 2nd highest of 21 |
| Revenue growth (TTM) | -5.8% | +7.6% | lowest of 21 |
| Operating margin | 22.7% | 17.0% | 4th highest of 21 |
| Forward P/E | 25.3× | 28.0× | 8th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 6.0% | 16.2% | 3rd least demanding of 18 |
| Growth delivered (Del g) | +6.7% | +8.3% | 8th lowest of 18 |
| Hurdle (Req g minus delivered) | -0.8 pp | +5.5 pp | 4th least demanding of 18 |
| ROIC minus cost of capital | +11.0 pp | +1.9 pp | 6th highest of 21 |
| EV / EBITDA | 16.7× | 20.2× | 9th cheapest of 18 |
| Net debt / EBITDA | 1.0× | 0.8× | 8th most indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sonova SOON.SW | Switzerland | $19.8B | +40% | -6% | 23% | 25.3× | 6.0% | +6.7% |
| Sartorius SRT.DE | Germany | $19.9B | +26% | +4% | 18% | 43.0× | 25.6% | +8.7% |
| Guardant Health GH | United States | $19.6B | +26% | +42% | -39% | n/a | n/a | n/a |
| Zimmer Biomet ZBH | United States | $19.6B | +21% | +7% | 16% | 11.7× | 7.4% | +3.2% |
| Straumann STMN.SW | Switzerland | $20.4B | +20% | +2% | 21% | 32.9× | 16.2% | +12.8% |
| Revvity RVTY | United States | $17.0B | +61% | +5% | 16% | 26.2× | 26.4% | -5.5% |
| Coloplast A/S COLO-B.CO | Denmark | $16.6B | +24% | +4% | 25% | 20.0× | -2.1% | +8.3% |
| Terumo 4543.T | Japan | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% | +13.0% |
| Sartorius Stedim Biotech DIM.PA | France | $24.2B | +32% | +4% | 19% | 45.7× | 33.4% | +9.2% |
| Steris STE | United States | $25.2B | +21% | +8% | 20% | 21.9× | 14.0% | +13.8% |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.4B | +4% | +27% | 9% | 45.7× | n/a | n/a |
| West Pharmaceutical Services WST | United States | $28.1B | +32% | +13% | 23% | 40.2× | 25.8% | +7.4% |
| Glaukos GKOS | United States | $13.8B | +62% | +47% | -9% | 161.5× | n/a | n/a |
| Lenskart Solutions LENSKART.NS | India | $13.6B | +49% | +35% | 10% | 137.7× | 53.2% | +33.5% |
| Baxter International BAX | United States | $13.5B | +39% | +5% | 6% | 12.7× | 13.4% | -0.7% |
| Dexcom DXCM | United States | $30.8B | +16% | +13% | 24% | 28.0× | 19.6% | +19.3% |
| Olympus 7733.T | Japan | $12.7B | +5% | +9% | 18% | 18.7× | -6.5% | +6.7% |
| Penumbra PEN | United States | $12.6B | -2% | +17% | 12% | 55.7× | 30.7% | +20.2% |
| Smith & Nephew SN..L | United Kingdom | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% | +5.6% |
| Illumina ILMN | United States | $31.8B | +48% | +6% | 21% | 35.2× | 27.2% | +6.0% |
| bioMerieux BIM.PA | France | $11.8B | +26% | -3% | 15% | 20.2× | 8.6% | +5.5% |